Molecular mechanisms of cisplatin resistance

Galluzzi, L, Senovilla, L, Vitale, I, Michels, J, Martins, I, Kepp, O, Castedo, M, Kroemer, G·2012·Oncogene
DOI 10.1038/onc.2011.384

Cited by (1,001)

Items 101–200 of 1,001

  1. Recent Developments in the Medicinal Applications of Silver-NHC Complexes and Imidazolium Salts
    Nicholas A. Johnson, Marie R. Southerland, Wiley J. Youngs · 2017 · Molecules
  2. Cisplatin for cancer therapy and overcoming chemoresistance
    Ranmali Ranasinghe, Michael L. Mathai, Anthony Zulli · 2022 · Heliyon
  3. What blocks more anticancer platinum complexes from experiment to clinic: Major problems and potential strategies from drug design perspectives
    Kun Peng, Bing‐Bing Liang, Wenting Liu, Zong‐Wan Mao · 2021 · Coordination Chemistry Reviews
  4. Mitochondrion-targeted platinum complexes suppressing lung cancer through multiple pathways involving energy metabolism
    Zhenzhu Zhu, Zenghui Wang, Changli Zhang, Yanjun Wang, Hongmei Zhang, Zhenji Gan, Zijian Guo, Xiaoyong Wang · 2019 · Chemical Science
  5. ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer
    Qiang Li, Alexis W. Damish, Zoë Frazier, David Liu, Elizaveta Reznichenko, Atanas Kamburov, Andrew Bell, HuiYong Zhao, Emmet Jordan, Sizhi Paul Gao et al. · 2018 · Clinical Cancer Research
  6. Mechanisms of cisplatin resistance and targeting of cancer stem cells: Adding glycosylation to the equation
    José Alexandre Ferreira, Andreia Peixoto, Manuel Neves, Cristiana Gaiteiro, Celso Albuquerque Reis, Yehuda G. Assaraf, Lúcio Lara Santos · 2015 · Drug Resistance Updates
  7. Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy
    Jiaqi Li, Jie Qing Eu, Li Ren Kong, Lingzhi Wang, Yaw Chyn Lim, Boon Cher Goh, Andrea Li‐Ann Wong · 2020 · Molecules
  8. Ovarian cancer stem cells more questions than answers
    Petronella Beatrix Ottevanger · 2017 · Seminars in Cancer Biology
  9. Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells
    Kyungsoo Ha, Warren C. Fiskus, Dong Soon Choi, Srividya Bhaskara, Leandro C. A. Cerchietti, Santhana G.T. Devaraj, Bhavin Shah, Sunil Sharma, Jenny C. Chang, Ari M. Melnick et al. · 2014 · Oncotarget
  10. Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort
    Howard A. Burris, Suzanne J. Bakewell, Johanna C. Bendell, Jeffrey R. Infante, Suzanne Fields Jones, David Robert Spigel, Glen J. Weiss, Ramesh K. Ramanathan, Angela Ogden, Daniel D. Von Hoff · 2016 · ESMO Open
  11. A miR-146a-5p/TRAF6/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance
    Qingcai Meng, Chen Liang, Jie Hua, Bo Zhang, Jiang Liu, Yiyin Zhang, Miaoyan Wei, Xianjun Yu, Jin Xu, Si Shi · 2020 · Theranostics
  12. Metal complexes as potential modulators of inflammatory and autoimmune responses
    Chung‐Hang Leung, Sheng Lin, Hai‐Jing Zhong, Dik‐Lung Ma · 2014 · Chemical Science
  13. Triple action Pt( iv ) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance
    Emanuele Petruzzella, Roman Sirota, Irene Solazzo, Valentina Gandin, Dan Gibson · 2018 · Chemical Science
  14. Trial Watch
    Erika Vacchelli, Alexander M.M. Eggermont, Catherine Sautès‐Fridman, Jérôme Galon, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi · 2013 · OncoImmunology
  15. Quantitative Evaluation of Cisplatin Uptake in Sensitive and Resistant Individual Cells by Single-Cell ICP-MS (SC-ICP-MS)
    Mario Corte‐Rodríguez, Roberto Álvarez-Fernández García, Elisa Blanco, Jörg Bettmer, María Montes‐Bayón · 2017 · Analytical Chemistry
  16. Reversal of cisplatin chemotherapy resistance by glutathione-resistant copper-based nanomedicine via cuproptosis
    Yao Lu, Qingqing Pan, Wenxia Gao, Yuji Pu, Bin He · 2022 · Journal of Materials Chemistry B
  17. Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells
    Mei‐Ling Han, Yifan Zhao, Caihong Tan, Yajie Xiong, Wenjuan Wang, Feng Ying Wu, Fei Yao, Long Wang, Zhong‐Qin Liang · 2016 · Acta Pharmacologica Sinica
  18. MicroRNA-148a-3p enhances cisplatin cytotoxicity in gastric cancer through mitochondrial fission induction and cyto-protective autophagy suppression
    Bowen Li, Weizhi Wang, Zheng Li, Zheng Chen, Xiaofei Zhi, Jianghao Xu, Qing Li, Lu Wang, Xiaoxu Huang, Linjun Wang et al. · 2017 · Cancer Letters
  19. Trial Watch
    Erika Vacchelli, Fernando Aranda, Alexander M.M. Eggermont, Jérôme Galon, Catherine Sautès‐Fridman, Isabelle Cremer, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi · 2014 · OncoImmunology
  20. Mechanisms of resistance to chemotherapy in non-small cell lung cancer
    Hye‐Young Min, Ho‐Young Lee · 2021 · Archives of Pharmacal Research
  21. Exploring the Tumor Microenvironment with Nanoparticles
    Lei Miao, Leaf Huang · 2015 · Cancer treatment and research
  22. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan
    the Liver Cancer Study Group of Japan, Kazuhiro Nouso, Koji Miyahara, D Uchida, Kenji Kuwaki, Namiki Izumi, Masao Omata, Takafumi Ichida, Masatoshi Kudo, Yonson Ku et al. · 2013 · British Journal of Cancer
  23. DNA damage response and resistance of cancer stem cells
    Etna Abad, Dmitry Graifer, Alex Lyakhovich · 2020 · Cancer Letters
  24. A highly annotated database of genes associated with platinum resistance in cancer
    Dongqing Huang, Sara R. Savage, Anna Pamela Calinawan, Chenwei Lin, Bing Zhang, Pei Wang, Timothy K. Starr, Michael J. Birrer, Amanda G. Paulovich · 2021 · Oncogene
  25. Sulforaphane Mediates Glutathione Depletion via Polymeric Nanoparticles to Restore Cisplatin Chemosensitivity
    Ying Xu, Xuexiang Han, Yiye Li, Huan Min, Xiao Zhao, Yinlong Zhang, Yingqiu Qi, Jian Ying Shi, Sheng Qi, Yongping Bao et al. · 2019 · ACS Nano
  26. Trial Watch: Targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapy
    Gwenola Manic, Florine Obrist, Antonella Sistigu, Ilio Vitale · 2015 · Molecular & Cellular Oncology
  27. Cisplatin prevents breast cancer metastasis through blocking early EMT and retards cancer growth together with paclitaxel
    Haitao Wang, Sen Guo, Seung-Jin Kim, Fangyuan Shao, Joshua W. K. Ho, Kuan Un Wong, Zhengqiang Miao, Dapeng Hao, Ming Zhao, Jun Xu et al. · 2020 · Theranostics
  28. Redox Paradox: A Novel Approach to Therapeutics-Resistant Cancer
    Luksana Chaiswing, William H. St. Clair, Daret K. St. Clair · 2018 · Antioxidants and Redox Signaling
  29. Emerging platinum( iv ) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment
    Zhigang Wang, Zhiqin Deng, Guangyu Zhu · 2019 · Dalton Transactions
  30. Targeting DNA Damage Response and Repair to Enhance Therapeutic Index in Cisplatin-Based Cancer Treatment
    Robert Csaba Kiss, Fen Xia, Scarlett Acklin · 2021 · International Journal of Molecular Sciences
  31. Anticancer metal drugs and immunogenic cell death
    Alessio Terenzi, Christine Pirker, Bernhard K. Keppler, Walter Berger · 2016 · Journal of Inorganic Biochemistry
  32. Acquisition of epithelial–mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/β-catenin/Snail signaling pathway
    Hao Wang, Ge Zhang, Huan Zhang, Fan Zhang, Binhua Zhou, Fen Ning, Hongsheng Wang, Shaohui Cai, Jun Du · 2013 · European Journal of Pharmacology
  33. The asymmetry of plasma membranes and their cholesterol content influence the uptake of cisplatin
    Timothée Rivel, Christophe Ramseyer, Semen O. Yesylevskyy · 2019 · Scientific Reports
  34. MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9
    Zhuo Dong, Zhiwei Zhong, Lihua Yang, Shaomin Wang, Zhaohui Gong · 2013 · Cancer Letters
  35. Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set
    Abdul Qader Sukkurwala, Sandy Adjemian, Laura Senovilla, Mickaël Michaud, Sabrina Spaggiari, Erika Vacchelli, Elisa Elena Baracco, Lorenzo Galluzzi, Laurence Zitvogel, Oliver Kepp et al. · 2014 · OncoImmunology
  36. Mitochondrial Involvement in Cisplatin Resistance
    Veronica Cocetta, Eugenio Ragazzi, Monica Montopoli · 2019 · International Journal of Molecular Sciences
  37. RETRACTED ARTICLE: miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer
    Jing Fang Sun, Xin Cai, Mingo M. H. Yung, Wei Zhou, Jing Li, Yi Zhang, Zhuqing Li, Stephanie S. Liu, Any Cheung, Hys Ngan et al. · 2018 · Oncogene · Retracted
  38. Ovarian Cancer—Insights into Platinum Resistance and Overcoming It
    Andrei Dan Havasi, Simona Sorana Cainap, Ana Teodora Havasi, Calin Ioan Cainap · 2023 · Medicina
  39. A bioinspired sulfur–Fe–heme nanozyme with selective peroxidase-like activity for enhanced tumor chemotherapy
    Shuaibing Zhang, Xuejiao J. Gao, Yuanjie Ma, Kexu Song, Mengyue Ge, Saiyu Ma, Lirong Zhang, Ye Yuan, Wei Jiang, Zhenzhen Wu et al. · 2024 · Nature Communications
  40. The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer
    Zhiguo Zheng, Hong Xu, Shasha Suo, Xiaoli Xu, Maowei Ni, Linhui Gu, Wei Chen, Liangyan Wang, Ye Zhao, Bing Tian et al. · 2016 · Scientific Reports
  41. The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair
    Diana Hwang Liang, Dong Soon Choi, Joe Ensor, Benny Abraham Kaipparettu, Barbara Lee Bass, Jenny C. Chang · 2016 · Cancer Letters
  42. Trial watch
    Laurie Menger, Erika Vacchelli, Oliver Kepp, Alexander M.M. Eggermont, Éric Tartour, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi · 2013 · OncoImmunology
  43. The protein disulfide isomerases PDIA4 and PDIA6 mediate resistance to cisplatin-induced cell death in lung adenocarcinoma
    Grégory Tufo, Aleck W.E. Jones, Z Wang, J Hamelin, Nicolas Tajeddine, Davide Degli Esposti, C. Martel, Céline Boursier, Cindy Gallerne, Camille Migdal et al. · 2014 · Cell Death and Differentiation
  44. Targeting YTHDF1 effectively re-sensitizes cisplatin-resistant colon cancer cells by modulating GLS-mediated glutamine metabolism
    Ping Chen, Xi-qiao Liu, Xiang Lin, Liying Gao, Shuo Zhang, Xuan Huang · 2021 · Molecular Therapy — Oncolytics
  45. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma—Mechanistics, review of phase III randomized clinical trials, and regulatory implications
    Ramez Nassef Eskander, Krishnansu S. Tewari · 2013 · Gynecologic Oncology
  46. Self-assembled nanoscale coordination polymers carrying siRNAs and cisplatin for effective treatment of resistant ovarian cancer
    Chunbai He, Demin Liu, Wenbin Lin · 2014 · Biomaterials
  47. SOX8 regulates cancer stem‐like properties and cisplatin‐induced EMT in tongue squamous cell carcinoma by acting on the Wnt/β‐catenin pathway
    Shuhua Xie, S. Fan, S.‐Y. Zhang, Wenbo Chen, Qing Li, Guokai Pan, Haoqiang Zhang, Weiwei Wang, Bingqing Weng, Zhongtang Zhang et al. · 2017 · International Journal of Cancer
  48. A Systematic Strategy of Combinational Blow for Overcoming Cascade Drug Resistance via NIR‐Light‐Triggered Hyperthermia
    Lingna Wang, Yingjie Yu, Dengshuai Wei, Lingpu Zhang, Xiaoyan Zhang, Guanxin Zhang, Dan Ding, Haihua Xiao, Deqing Zhang · 2021 · Advanced Materials
  49. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic
    Aniello Cerrato, Francesco Morra, Angela Celetti · 2016 · Journal of Experimental & Clinical Cancer Research
  50. The Pentose Phosphate Pathway and Its Involvement in Cisplatin Resistance
    Isabella Giacomini, Eugenio Ragazzi, Gianfranco Pasut, Monica Montopoli · 2020 · International Journal of Molecular Sciences
  51. Quercetin Enhances Cisplatin Sensitivity of Human Osteosarcoma Cells by Modulating microRNA-217-KRAS Axis
    Xian Zhang, Qing-Gong Guo, Jingtao Chen, Zhaohui Chen · 2015 · Molecules and Cells
  52. Cyclometalated Ir( iii ) complexes as targeted theranostic anticancer therapeutics: combining HDAC inhibition with photodynamic therapy
    Rui‐Rong Ye, Cai‐Ping Tan, Liang He, Mu‐He Chen, Liang‐Nian Ji, Zong‐Wan Mao · 2014 · Chemical Communications
  53. Withaferin A Alone and in Combination with Cisplatin Suppresses Growth and Metastasis of Ovarian Cancer by Targeting Putative Cancer Stem Cells
    Sham S. Kakar, Mariusz Z. Ratajczak, Karen S. Powell, Mana Moghadamfalahi, Donald Max Miller, Surinder K. Batra, Sanjay K. Singh · 2014 · PLoS ONE
  54. Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines
    Lynne Sawers, Michelle Ferguson, Bianca Ihrig, H C Young, Probir Chakravarty, C. Roland Wolf, Gillian C. Smith · 2014 · British Journal of Cancer
  55. Inhibition of glucose-6-phosphate dehydrogenase sensitizes cisplatin-resistant cells to death
    Daniela Catanzaro, Edoardo Gaude, Genny Orso, Carla Giordano, Giulia Guzzo, Andrea Rasola, Eugenio Ragazzi, Laura Caparrotta, Christian Frezza, Monica Montopoli · 2015 · Oncotarget
  56. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles
    Ana Vanessa Nascimento, Amit Singh, Hassan Bousbaa, Domingos Ferreira, Bruno Filipe Carmelino Cardoso Sarmento, Mansoor M. Amiji · 2016 · Acta Biomaterialia
  57. Charge-reversal nanocarriers: An emerging paradigm for smart cancer nanomedicine
    Mingzhen Zhang, Xiaoxiao Chen, Chao Li, Xian Shen · 2019 · Journal of Controlled Release
  58. Targeting HNRNPU to overcome cisplatin resistance in bladder cancer
    Zhenduo Shi, Lin Hao, Xiaoxiao Han, Zhuo‐Xun Wu, Kun Pang, Yang Dong, Jiaxin Qin, Guangyue Wang, Xuanming Zhang, Tian Xia et al. · 2022 · Molecular Cancer
  59. YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage
    Eric Stefano Ciamporcero, He Shen, Swathi Ramakrishnan, Sheng‐Yu Ku, Sreenivasulu Chintala, Li Shen, Remi M. Adelaiye-Ogala, Kiersten Marie Miles, Chiara Ullio, Stefania Pizzimenti et al. · 2015 · Oncogene
  60. Antitumor Activity of 7-Aminocarboxycoumarin Derivatives, a New Class of Potent Inhibitors of Lactate Influx but Not Efflux
    Nihed Draoui, Olivier Schicke, Emmanuel Seront, Caroline Bouzin, Pierre Sonveaux, Olivier Riant, Olivier Féron · 2014 · Molecular Cancer Therapeutics
  61. C/EBPβ enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation
    Dan Liu, Xiaoxue Zhang, Mengchen Li, Canhui Cao, Dongyi Wan, Bixin Xi, Jiahong Tan, Ji Wang, Zongyuan Yang, Xinxia Feng et al. · 2018 · Nature Communications
  62. Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance
    David P. Hill, Akeena Harper, Joan Malcolm, Monica McAndrews-Hill, Susan M. Mockus, Sara E. Patterson, Timothy Reynolds, Erich J. Baker, Carol J. Bult, Elissa J. Chesler et al. · 2019 · BMC Cancer
  63. Cisplatin induces the release of extracellular vesicles from ovarian cancer cells that can induce invasiveness and drug resistance in bystander cells
    Priya Samuel, Laura Ann Mulcahy, Fiona M. Furlong, Helen O. McCarthy, Susan Ann Brooks, Muller Fabbri, Ryan Charles Pink, David R. F. Carter · 2017 · Philosophical Transactions of the Royal Society B Biological Sciences
  64. Induction of autophagy contributes to cisplatin resistance in human ovarian cancer cells
    Lingjie Bao, Melba C. Jaramillo, Zhenbo Zhang, Yunxi Zheng, Ming Yao, DONNA D. ZHANG, Xiaofang Yi · 2014 · Molecular Medicine Reports
  65. Metal-Based Antitumor Compounds: Beyond Cisplatin
    Peter V. Simpson, Nima Maheshkumar Desai, Ilaria Casari, Massimiliano Massi, Marco Falasca · 2019 · Future Medicinal Chemistry
  66. The balance between NRF2/GSH antioxidant mediated pathway and DNA repair modulates cisplatin resistance in lung cancer cells
    Matheus Molina Silva, Clarissa Ribeiro Reily Rocha, Gabriela Sarti Kinker, Alessandra Luíza Pelegrini, Carlos Frederico Martins Menck · 2019 · Scientific Reports
  67. CircRNAs in anticancer drug resistance: recent advances and future potential
    Tianwei Xu, Mengwei Wang, Lihua Jiang, Li Ma, Li Wan, Qinnan Chen, Chenchen Wei, Zhaoxia Wang · 2020 · Molecular Cancer
  68. Naturally derived indole alkaloids targeting regulated cell death (RCD) for cancer therapy: from molecular mechanisms to potential therapeutic targets
    Rui Qin, Feng-Ming You, Qian Zhao, Xin Xie, Cheng Peng, Gu Zhan, Bo Han · 2022 · Journal of Hematology & Oncology
  69. Clinical and Translational Oncology
    2013 · Clinical & Translational Oncology
  70. Roles of Epithelial-Mesenchymal Transition in Cancer Drug Resistance
    Yulong Shang, Xiqiang Cai, Daiming Fan · 2013 · Current Cancer Drug Targets
  71. Metabolic vulnerability of cisplatin‐resistant cancers
    Florine Obrist, Judith Michels, Sylvère Durand, Alexis Chery, Jonathan G. Pol, Sarah Lévesque, Adrien Joseph, Valentina Astesana, Federico Pietrocola, Gen Sheng Wu et al. · 2018 · The EMBO Journal
  72. PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models
    Takahiro Yamazaki, Aitziber Buqué, Tyler David Ames, Lorenzo Galluzzi · 2020 · OncoImmunology
  73. Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy
    Lukáš Górecki, Martin Andrš, Martina Řezáčová, Jan Korábečný · 2020 · Pharmacology & Therapeutics
  74. Metallomics insights into the programmed cell death induced by metal-based anticancer compounds
    Cai‐Ping Tan, Yiying Lu, Liang‐Nian Ji, Zong‐Wan Mao · 2014 · Metallomics
  75. Exosomes as mediators of platinum resistance in ovarian cancer
    Jennifer Crow, Safinur Atay, Samagya Banskota, Brittany Artale, Sarah Schmitt, Andrew K. Godwin · 2017 · Oncotarget
  76. A global burden of gastric cancer: the major impact of China
    Yongzhan Nie, Kaichun Wu, Jun Qing Yu, Qiaoyi Liang, Xiqiang Cai, Yulong Shang, Jinfeng Zhou, Kai‐Feng Pan, Liping Laura Sun, Jing‐Yuan Fang et al. · 2017 · Expert Review of Gastroenterology & Hepatology
  77. Upregulation of miR-21 in Cisplatin Resistant Ovarian Cancer via JNK-1/c-Jun Pathway
    Echevarría-Vargas, Ileabett M., Valiyeva, Fatma, Vivas-Mejía, Pablo E. · 2014 · PLoS ONE
  78. Overexpression of glypican-1 implicates poor prognosis and their chemoresistance in oesophageal squamous cell carcinoma
    Hisashi Hara, Tsuyoshi Takahashi, Satoshi Serada, Minoru Fujimoto, Tomoharu Ohkawara, Rie Nakatsuka, Emi Harada, Takahiko Nishigaki, Yusuke Takahashi, Satoshi Nojima et al. · 2016 · British Journal of Cancer
  79. Role of Nucleotide Excision Repair in Cisplatin Resistance
    Mingrui Duan, Jenna Ulibarri, Ke Jian Liu, Peng Mao · 2020 · International Journal of Molecular Sciences
  80. A new endoplasmic reticulum-targeted two-photon fluorescent probe for imaging of superoxide anion in diabetic mice
    Haibin Xiao, Xiao Liu, Chuanchen Wu, Yaohuan Wu, Ping Li, Xiaomeng Guo, Bo Tang · 2017 · Biosensors and Bioelectronics
  81. Phytochemicals: Current strategy to sensitize cancer cells to cisplatin
    Chao‐Yue Sun, Qian-Yu Zhang, Guangjuan Zheng, Bing Feng · 2018 · Biomedicine & Pharmacotherapy
  82. Pt(II) and Au(III) complexes containing Schiff-base ligands: A promising source for antitumor treatment
    Ying Jie Sun, Yunlong Lu, Mianli Bian, Zhibin Yang, Xiaoyan Ma, Wukun Liu · 2020 · European Journal of Medicinal Chemistry
  83. Artesunate Impairs Growth in Cisplatin-Resistant Bladder Cancer Cells by Cell Cycle Arrest, Apoptosis and Autophagy Induction
    Fuguang Zhao, Olesya Vakhrusheva, Sascha D. Markowitsch, Kimberly Sue Slade, Igor Tsaur, Jindrich Jr. Cinatl, Martin Michaelis, Thomas Efferth, Axel Haferkamp, Eva Juengel · 2020 · Cells
  84. Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer
    Steffan T. Nawrocki, Kevin R. Kelly, Peter G. Smith, Claudia M. Espitia, Anthony P. Possemato, Sean A. Beausoleil, Michael A. Milhollen, Stephen J. Blakemore, Michael Thomas, Allison Berger et al. · 2013 · Clinical Cancer Research
  85. Nanomedicine to target multidrug resistant tumors
    Élise Lepeltier, Patrícia Mendonca Rijo, Flavio Rizzolio, Rachela Popovtzer, Vilma Petrikaitė, Yehuda G. Assaraf, Catherine Passirani · 2020 · Drug Resistance Updates
  86. Copper in cancer: From pathogenesis to therapy
    Defeng Guan, Lihui Zhao, Xin Shi, Xiaoling Ma, Zhou Chen · 2023 · Biomedicine & Pharmacotherapy
  87. Trial Watch: Peptide-based anticancer vaccines
    Jonathan G. Pol, Norma Bloy, Aitziber Buqué, Alexander M.M. Eggermont, Isabelle Cremer, Catherine Sautès‐Fridman, Jérôme Galon, Éric Tartour, Laurence Zitvogel, Guido Kroemer et al. · 2015 · OncoImmunology
  88. Trial watch
    Erika Vacchelli, Lorenzo Galluzzi, Wolf H. Fridman, Jérôme Galon, Catherine Sautès‐Fridman, Éric Tartour, Guido Kroemer · 2012 · OncoImmunology
  89. Targeting DNA repair, DNA metabolism and replication stress as anti‐cancer strategies
    Jordi Carreras Puigvert, Kumar Sanjiv, Thomas Helleday · 2015 · FEBS Journal
  90. Cisplatin resistance in germ cell tumours: models and mechanisms
    C. Jacobsen, Friedemann U. Honecker · 2014 · Andrology
  91. Trial Watch
    Fernando Aranda, Erika Vacchelli, Alexander M.M. Eggermont, Jérôme Galon, Wolf H. Fridman, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi · 2014 · OncoImmunology
  92. Role of Exosomal miRNAs and the Tumor Microenvironment in Drug Resistance
    Patrick Wellington da Silva dos Santos, Fausto Bruno dos Reis Almeida · 2020 · Cells
  93. Molecular targets for anticancer redox chemotherapy and cisplatin-induced ototoxicity: the role of curcumin on pSTAT3 and Nrf-2 signalling
    Anna Rita Fetoni, Fabiola Paciello, Daniele Mezzogori, Rolando Rolesi, Sara Letizia Maria Eramo, Gaetano Paludetti, Diana Troiani · 2015 · British Journal of Cancer
  94. Involvement of SRPK1 in cisplatin resistance related to long non-coding RNA UCA1 in human ovarian cancer cells
    F. WANG, Jixiang Zhou, Xiaohong Xie, Jinjing Hu, L. CHEN, Qing Hu, H. GUO, Chao Yu · 2015 · Neoplasma
  95. Exosome-Delivered c-Met siRNA Could Reverse Chemoresistance to Cisplatin in Gastric Cancer
    Qiumo Zhang, Haiyang Zhang, Tao Ning, Dongying Liu, Ting Deng, Rui Liu, Ming Bai, Kegan Zhu, Jialu Li, Fan Qian et al. · 2020 · International Journal of Nanomedicine
  96. ERCC1-Positive Circulating Tumor Cells in the Blood of Ovarian Cancer Patients as a Predictive Biomarker for Platinum Resistance
    Jan Dominik Kuhlmann, Pauline Wimberger, Ágnes Bánkfalvi, Thomas Keller, S Schöler, Bahriye Aktas, Paul Buderath, Siegfried Hauch, Friedrich Otterbach, Rainer Kimmig et al. · 2014 · Clinical Chemistry
  97. Conjugation of Cisplatin Analogues and Cyclooxygenase Inhibitors to Overcome Cisplatin Resistance
    Wilma Neumann, Brenda C. Crews, Menyhárt B. Sárosi, Cristina M. Daniel, Kebreab Ghebreselasie, M. Scholz, Lawrence J. Marnett, Evamarie Hey‐Hawkins · 2014 · ChemMedChem
  98. Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells
    Leli Zeng, Yu Chen, Jiangping Liu, Huaiyi Huang, Ruilin Guan, Liang‐Nian Ji, Hui Chao · 2016 · Scientific Reports
  99. Inhibition of endotrophin, a cleavage product of collagen VI, confers cisplatin sensitivity to tumours
    Jiyoung Park, Thomas S. Morley, Philipp E. Scherer · 2013 · EMBO Molecular Medicine
  100. Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling
    LH Wang, Yi Li, Yang Sn, F-Y Wang, Yue Hou, Wei Cui, K Chen, Qi Cao, Shuang Wang, Zhang Ty et al. · 2013 · British Journal of Cancer